SecBot SecBot
PRESS-RELEASE ·Filed Jul 9, 2026

NRIX

Nurix Therapeutics, Inc.
BULLISH
Impact 8/10
Horizondays Processed4mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The Roche collaboration transforms the risk/reward profile, investors should watch for the HSR/antitrust clearance timeline (expected Q3) triggering the $700M payment. Key catalysts ahead: DAYBreak CLL-201 pivotal data, Phase 1b combo data at upcoming medical meetings, and initiation of Phase 2 in CSU/MS. The $0.81 EPS miss vs -$0.72 consensus is backward-looking noise given the platform validation; focus on enrollment updates for the registrational CLL trial.

DirectionBullish
Confidencehigh
Horizondays

Drugs in focus

NRIX drug pipeline →

bexobrutideg

▲ Bullish Named in this press release
Impact
Phase
Phase 1a/b (pivotal Phase 2 underway; Phase 3 planned summer 2026)
Time to market
3-5 years (Phase 3 trials starting summer 2026; potential accelerated approval pathway via pivotal Phase 2 data could compress timeline)
Next catalyst
None dated

What to watchThe Roche deal ($700M upfront, up to $2.3B total) already provided the major derisking catalyst, the stock surged ~70% on the June 8 announcement. Watch for HSR antitrust clearance (expected Q3 2026), Phase 3 trial initiation in CLL this summer, and any early data from planned Phase 2 starts in autoimmune (CSU) and neurology (MS). Analyst consensus is Strong Buy with mean PT of $31.44, but the stock already reflects significant partnership premium, new upside will require compelling Phase 2/3 data execution, not just partnership validation.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$23.06
T+0 close · Jul 9, 2026 · via day close
Latest settled
−0.78%
T+60 · $22.88
Vs SPY
−3.41%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 10 $23.06entry
  2. T+1 · 4mo ago −1.52%α −0.75% · $22.71
  3. T+5 · 4mo ago +0.04%α +0.60% · $23.07
  4. T+20 · 3mo ago +10.71%α +8.29% · $25.53
  5. T+60 · 6w ago −0.78%α −3.41% · $22.88
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Nurix reported Q1 FY2026 revenue of $9.0M (consensus $15.3M, -41% miss) and EPS of -$0.81 vs consensus -$0.72 (-12.5% miss) following a year-ago quarter that included $30M in license fees. The revenue miss is largely explained by the absence of the prior-year Sanofi license payments, but the operational spend ramp (R&D up 12% YoY) drove net loss to -$89.5M vs -$43.5M. The dominant positive event is the global Roche collaboration for bexobrutideg, which brings a $700M near-term cash infusion (expected closing in Q3) and total potential milestones of $2.3B, dramatically extending the cash runway to ~$1.14B pro-forma and validating the BTK degrader platform across oncology, immunology, and neurology.

Key Financial Metrics

EPS
−$0.81
est −$0.72 · -12.5%
Revenue
$9.0M
est $15.3M · -40.9% · -79.5% YoY
Rating
miss

Key Facts

  • Revenue $9.0M miss vs consensus $15.3M (-41%); prior year $44.1M included $30M in Sanofi license fees
  • EPS -$0.81 miss vs consensus -$0.72 (-12.5%); prior year -$0.52
  • Net loss -$89.5M vs -$43.5M; R&D spend $87.7M (+12% YoY)
  • Cash/investments $443.5M as of May 31, 2026; pro-forma ~$1.14B after Roche upfront
  • Roche collaboration: $700M upfront (expected Q3 FY26), up to $2.3B total milestones; 40/60 cost split; 50/50 US profit share
  • Bexobrutideg pivotal CLL trial (DAYBreak CLL-201) ongoing; Phase 3 vs pirtobrutinib expected mid-2026
  • Phase 1b ORR 92.9% (Cohort 5) and 84.2% (Cohort 15) in CLL; median PFS 22.1 mo
  • Expansion planned into CSU Phase 2 and MS Phase 2
  • Sanofi milestone earned $2M; Gilead IRAK-4 degrader in Phase 1; Pfizer DAC programs ongoing

Financial Impact

$700M near-term cash injection via Roche upfront; total deal value up to $2.3B inclusive of milestones; 40/60 cost sharing reduces future R&D cash burden

cash runwayR&D expenditurenet lossrevenue

Risk Factors

  • Roche collaboration subject to HSR and antitrust clearances, delay or failure to close
  • Pivotal CLL trial DAYBreak CLL-201 may not support Accelerated Approval
  • Bexobrutideg faces competitive pressure from pirtobrutinib and other BTK inhibitors/degraders
  • Net loss expanding: -$176.7M year-to-date vs -$99.8M prior year; operational burn ~$100M/quarter
  • Cash/equivalents $67.7M low vs near-term $700M Roche payment, any delay strains liquidity

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3325185

Track record

33 reports on NRIX

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +53.71% at T+20 after the Jun 8, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.17 Now $14.73 −2.90% settles Dec 15
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.41 Now $14.73 −4.41% settles Dec 15
  4. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
  5. Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
  6. Nov 4, 202612d ago 144 Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
  7. Nov 3, 202613d ago 144 Neutral 2/10 Entry $15.95 Now $14.73 −7.65% settles Dec 3
  8. Nov 3, 202613d ago 8-K Bearish 5/10 Entry $15.95 Now $14.73 +7.65% settles Dec 3
  9. Nov 2, 202614d ago Insider Cluster Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
  10. Nov 2, 202614d ago 144 Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
Showing 10 of 33

US Market Status

Market Closed · Opens Wed (10h 43m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 9, 2026